🔗 Share this article

Given that the United States continues making historic revisions to its immunization schedules, a particular individual has surfaced somewhat surprisingly: Høeg, an American of Danish descent sports physician and public health researcher who first made her name by expressing skepticism about coronavirus vaccinations throughout the pandemic and has concentrated on alleged deaths following Covid vaccination in her short position at the US Food and Drug Administration (FDA).

Proposed Overhauls to Childhood Vaccine Schedule

Health officials had intended to reveal sweeping revisions to the pediatric vaccine schedule recently, bringing the US with Denmark’s immunization schedule, according to reports – a significant shift that would place the US at odds with much of the international standard with insufficient data for benefit. The planned update has been pushed back until the new year.

Instead of Vinay Prasad, Dr. Høeg is set to speak at the meeting. She was newly appointed acting director of the FDA’s CDER, the fifth person to head the office this calendar year.

A New Direction at the Regulatory Body

Høeg's temporary position could signify a closer partnership between the pharmaceutical and vaccine divisions as Høeg and Prasad consolidate power at the FDA – and it signals a renewed priority upon reevaluating long-standing immunizations at the FDA.

Høeg has repeatedly called for halting certain pediatric immunization guidelines in the US in order to be more like the Danish model, a country with nationalized medicine and a citizenry about the size of Wisconsin’s.

In her initial public appearances, she has persisted in emphasizing on immunizations – traditionally the domain of Prasad, director of the FDA’s CBER – rather than medication approval.

Doubts Over Expertise

Høeg has no apparent track record in drug development, regulation or leadership, which has been customary for past heads of the biologics center. She has worked at the FDA as a senior adviser to the commissioner and the vaccine center since March.

“It seems she lacks to have any of the qualifications” for leading the pharmaceutical oversight division, said a neurologist and psychiatrist. “She has not conducted a clinical trial. She has no expertise in managing a large organization. She lacks background in drug approvals.”

Past directors of the center would “grasp laws and regulations and the underlying principles of drug development”, said Janet Woodcock. “Objectively, she lacks the sort of resume that prior appointees who ran the center have had.”

The drug center has an enormous portfolio at the FDA, Woodcock emphasized.

“Everybody just pays attention on the new drug program, but the generic program approves a multitude of generic drugs. There is also a biologic copycat branch, over-the-counter program and so forth, and every single one must be looked after,” Woodcock said. “The responsibility you overlook, that is the part that I always told people is going to cause problems.”

Additionally, a substantial management aspect to the position, which oversees in excess of 5,000 personnel. “It’s a massive management job, if you execute it properly,” she added.

Response and Contentious Initiatives

Regarding concerns about Høeg’s fitness for the role and whether this appointment signifies increased cooperation among agency officials on vaccines, a spokesperson said that the “concerns stem from flawed assumptions”.

“Her experience aligns with the duties of her job,” the spokesperson explained, pointing to the months Høeg spent counseling the FDA commissioner on “pharmaceutical safety and oversight research, including computerized risk analysis and vaccine surveillance”.

In her interim role, Høeg assumes responsibility for the agency head's new fast-track approval initiative, a contentious rapid drug-approval program that allegedly worried her predecessors. “How are these drugs being picked for this fast-track system? Who takes the calls?” Dr. Howard questioned. “There is a lot of secrecy occurring at the regulatory body right now.”

Broadly speaking, he stated, “the Food and Drug Administration seems to be moving towards laxer regulations of all drugs, aside from immunizations.”

Public Track Record on Immunizations

With immunizations, Høeg has a more documented, if concerning, past, critics said. She released a study using unverified public submissions to determine the rate of myocarditis following COVID-19 vaccination. She counseled the state of Florida surgeon general Dr. Joseph Ladapo, who was said to have altered data to indicate Covid vaccinations are pose a greater threat than they are.

Among her “desired changes” for the incoming government featured revising guidelines for recently developed shots and ending “unnecessary” vaccines, she stated after the election on a audio program. At the FDA, Høeg has allegedly floated the idea of preventing teenage boys from receiving Covid vaccines.

“She’s an all-around true believer who begins with her beliefs and works backwards to retrofit the evidence in a highly misleading, untruthful fashion,” Dr. Howard argued.

Gaining Influence and a “Push for Payback”

Høeg became part of fellow skeptics, {like|